Innovation & geistiges Eigentum · 22.5.19961 Min. Lesezeit
Notice of Two Year Exclusivity Period; DAYPRORegister Oxaprozin
Lokale automatische Übersetzung · Originalsprache der Quelle
Zusammenfassung
The Patent and Trademark Office has received notification from G. D. Searle & Co. that it claims entitlement under section 2105 of the FDA Export Reform and Enhancement Act of 1996 (Chapter 1A of Pub. L. No. 104-134) for its drug product DAYPRO oxaprozin.